BIOGNOSYS
Indivumed, developer of the world’s leading discovery platform for precision oncology, and Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today that they are extending their strategic partnership to provide biopharma customers with immunopeptidomics insights for oncology drug discovery.
The partnership is driven by each company’s unique capabilities in omics research, with Biognosys bringing industry-leading mass spectrometry-based proteomics technology and solutions, and Indivumed providing high-quality samples and data as well as its multi-omics based AI discovery system, nRavel® .
The initial partnership established in December 2019 focused on enriching Indivumed’s IndivuType multi-omics cancer database with proteome-level data from thousands of samples analyzed by Biognosys. Since then, Indivumed and Biognosys have successfully collaborated on various clinical research projects and published results from a large-scale study in lung cancer at AACR 2020 , revealing new biomarkers for tumor biology. Building on this success, the companies are now extending their partnership with immunopeptidomics research.
Immunopeptides play an essential role in the immune system and can be analyzed to support the development of personalized treatments, especially in cancers, vaccines, infectious, and autoimmune diseases. Mass spectrometry is currently the only technology that can reliably measure and identify immunopeptide profiles of biological samples on a large scale.
Biognosys’ immunopeptidomics workflow deploys its patented Hyper Reaction Monitoring (HRM™) mass spectrometry technology for proteome quantification in combination with its proprietary Spectronaut™ and SpectroMine™ data analysis software to identify over 10,000 unique immunopeptides from low amounts of sample material. The workflow is highly efficient and scalable for use in large-scale clinical studies.
Indivumed then can provide biopharma customers further validation and insights on the immunopeptide signatures identified through Biognosys’ workflow, based on its IndivuType, global multi-omics cancer database and its analytics platform nRavel® to enhance R&D activities and new discovery programs for individualized therapy.
Biognosys will present validation of the workflow sensitivity and reproducibility at the American Society of Mass Spectrometry (ASMS) Annual Conference on Nov 1st in Philadelphia, while Indivumed will present clinically relevant multi-omic analysis at the BioData World Congress on Nov 2nd in Basel.
The new immunopeptidomics offering is already being applied successfully with third party biopharma companies to enhance their drug discovery efforts.
Lukas Reiter, PhD, Chief Technology Officer of Biognosys states: “Biognosys’ HRM™ technology uniquely addresses key challenges in immunopeptidomics research. Using only small amounts of tissue, our optimized workflow provides deep and comprehensive biological insights on the immune system. We are thrilled to apply this solution on the valuable tissue samples from Indivumed and support drug discovery in areas of high unmet need.”
Roald Forsberg, Chief Business Officer and Head of IndivuType Business Unit at Indivumed commented: “With our unique IndivuType database and our nRavel® AI system we have a fantastic opportunity to make new discoveries regarding the role of the immune response in the tumor microenvironment and to develop new immunotherapies against cancer. This extended partnership with Biognosys gives us the ability to validate and expand our findings using state-of-the-art mass-spectrometry technology which will accelerate our path towards bringing these discoveries into the practice of personalized oncology.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
About Indivumed
Driven by our mission to unveil the complex mechanisms of cancer and to advance precision oncology, Indivumed combines the world’s most comprehensive multi-omics data with extensive medical experience, bioinformatics expertise, and AI-integrated advanced analytics. Our global clinical network enables us to collect and analyze thousands of patient samples using a standardized approach to ensure biospecimen quality across three business units – IndivuServ, IndivuTest, and IndivuType. The unparalleled depth and quality of our data – coupled with our robust product and service offerings – gives us the ability to obtain novel insights and accelerate cancer research. For more information, visit www.indivumed.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005054/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
Andersen Consulting udvider sine kapaciteter inden for digital transformation5.12.2025 16:53:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Neit Consulting, et firma med fokus på at skabe mere effektiv drift, integrere intelligente teknologier og accelerere den digitale modenhed for kunder. Neit Consulting er et konsulentfirma med base i Tjekkiet og mere end 20 års erfaring med at levere ISO-certificerede it- og forretningsrådgivningsydelser inden for dataanalyse, performance management og procesoptimering. Med mere end 200 konsulenter hjælper firmaet kunder – herunder globale banker, forsikringsselskaber, produktionsvirksomheder og offentlige instanser –gennem virksomhedsrådgivning, implementering af it-systemer og langsigtet systemsupport. Neit Consulting betjener kunder internationalt med fokus på at afstemme digital kapacitet med komplekse driftsmæssige behov. "Dette samarbejde afspejler et markant fremskridt i omfanget af de ydelser, vi tilbyder vores kunder," udtaler Tomáš Niederle, salgsdirektør for Neit Consulting. "Andersens globale rækkevidde og tværfaglige tilga
Fitch Learning Completes Acquisition of Moody’s Analytics Learning Solutions and the Canadian Securities Institute5.12.2025 16:48:00 CET | Press release
Combined entity to accelerate financial services skills development and drive measurable business outcomes across 148 countries Fitch Learning, the global leader in financial learning and professional certifications, today announced the completion of its acquisition of Moody’s Analytics Learning Solutions (MALS) and the Canadian Securities Institute (CSI). MALS is a global provider of credit and digital learning, and CSI is a leading provider of certifications for the Canadian financial services industry. Fitch Learning, recognized globally as the premier financial education provider, delivers specialized training for the financial services industry through accredited qualifications, flexible corporate solutions programs, managed services and digital learning solutions trusted by leading institutions worldwide. The combined business will serve over 92,000 finance professionals across 148 countries, at every stage of their careers. “This acquisition is about creating more opportunities
Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation5.12.2025 16:00:00 CET | Press release
Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design, develop, and operate a portfolio of digital and AI solutions aimed at improving efficiency and automating complex business processes. The launch of this new company is the direct outcome of a year of successful collaboration between the two firms and marks a new phase in their shared ambition to bring scalable, high-performance digital solutions to market, aiming to further augment their clients’ capacity to compress time to impact in a variety of domains. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205465303/en/ Arthur D. Little and Vega IT have announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design, develop, and operate a portfolio of digital and AI solutions. Axceler8 Solutions’ first product, Axceler8 Rx, is now live as a newly developed platform, and is a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom